ProSolus, subsidiary of Mission Pharmacal dedicated to transdermal and trans-mucosal drug delivery products, has expanded manufacturing capabilities.
ProSolus has expanded its commercial manufacturing capabilities by installing a second transdermal production facility as part of the manufacturing location in Boerne, Texas (USA).
While both ProSolus facilities will continue manufacturing transdermal products, the Boerne location houses a larger production line than the Miami site, more than doubling the company's total transdermal product output.
Combined, the capacity of the two locations is now more than 100 million patches annually.
Led by industry veteran Jim Self, the new ProSolus commercial team will provide potential partners throughout the pharmaceutical industry direct access to the esearch, development, and manufacturing capabilities of ProSolus.
Partners can capitalise on the ProSolus team's extensive experience in all phases of product development, from formulation development and regulatory filing to commercial scale manufacturing.
They also are adept at developing new NDA and ANDA prescription products, as well as over-the-counter consumer products.